AstraZeneca yakira imbaraga zo kugenzura imiti ya oncology

Ku wa kabiri, AstraZeneca yakiriye inshuro ebyiri mu nshingano zayo za oncology, nyuma y’uko abagenzuzi b’Amerika n’Uburayi bemeye gutanga amabwiriza agenga imiti y’ibiyobyabwenge, intambwe yambere yo gutsindira kwemerwa niyi miti.

Uruganda rukora ibiyobyabwenge muri Anglo-Suwede, hamwe na MedImmune, ishami ry’ubushakashatsi ku iterambere ry’ibinyabuzima ku isi, batangaje ko Ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) cyemeye gusaba uruhushya rwa moxetumomab pasudotox, umuti mushya ushobora kuvura abarwayi bakuze bafite selile y’imisatsi. leukemia (HCL) yakiriye byibuze imirongo ibiri yabanje kwivuza.

FDA yahaye imiti “isuzuma ryambere”, ihabwa imiti, iyo byemejwe, izatanga iterambere ryinshi mu kuvura, gusuzuma, cyangwa gukumira indwara zikomeye. Icyemezo giteganijwe mu gihembwe cya gatatu cy'uyu mwaka.

Ku rundi ruhande, ikigo cy’ubuvuzi cy’ibihugu by’i Burayi cyakiriye amabwiriza agenga Lynparza, ikiyobyabwenge AstraZeneca ubu ifatanije na 50:50 ku bufatanye na Merck, isosiyete ikora ibiyobyabwenge muri Amerika, mu kuvura kanseri y'ibere ikwirakwira ahandi mu mubiri ku barwayi bafite umwihariko. ihindagurika ry'imiterere.

Niba byemejwe, imiti izaba iyambere ya PARP inhibitori yo kuvura kanseri yamabere i Burayi. PARP ni poroteyine iboneka mu ngirabuzimafatizo z'umuntu ifasha izo selile kwikosora iyo zangiritse. Muguhagarika iki gikorwa cyo gusana kanseri ya kanseri, inhibitor za PARP zifasha selile gupfa.

Lynparza muri Mutarama abaye inzitizi ya mbere ya PARP yemewe ahantu hose ku isi kanseri y'ibere, ubwo yatsindaga abategetsi ba Amerika.

Mu igeragezwa riheruka, Lynparza yongereye cyane ubuzima butagira amajyambere ugereranije na chimiotherapie kandi bigabanya ibyago byo kwandura indwara cyangwa gupfa ku kigero cya 42%.

Muri 2017 icya gatanu cyibicuruzwa bya Astra byaturutse kuri oncology kandi isosiyete iteganya ko iki gipimo kizamuka. Imigabane mu itsinda yafunze 0,6 ku ijana kuri £ 49.26.

Mu iterambere ritandukanye, Compugen, isosiyete ikora ibya farumasi yo muri Isiraheli, yavuze ko yagiranye amasezerano yihariye na MedImmune izafasha iterambere ry’ibicuruzwa bya antibody bivura kanseri.

Compugen yagize ati: MedImmune ifite uburenganzira bwo gukora ibicuruzwa byinshi munsi y’uruhushya “kandi bizashingwa gusa ubushakashatsi, iterambere ndetse n’ibikorwa by’ubucuruzi mu masezerano”.

Isosiyete yo muri Isiraheli izahabwa amadorari miliyoni 10 y’imbere kandi yemerewe kwakira amadolari agera kuri 200 $ mu iterambere, amabwiriza agenga ubucuruzi n’ibikorwa by’ubucuruzi ku bicuruzwa bya mbere, ndetse n’imisoro ku bicuruzwa bizaza.

Umuyobozi mukuru wa Compugen, Anat Cohen-Dayag, yavuze ko aya masezerano “adufasha kubona amafaranga y’iterambere ry’ubumenyi muri gahunda zacu, mu gihe dukomeje guteza imbere gahunda zacu mu bigeragezo by’amavuriro”.